WO2024218655 - COMPOSITIONS AND METHODOLOGY FOR DELIVERY OF ALPHA-GALACTOSYLCERAMIDE COMPOUNDS
National phase entry is expected:
Publication Number
WO/2024/218655
Publication Date
24.10.2024
International Application No.
PCT/IB2024/053714
International Filing Date
16.04.2024
Title **
[English]
COMPOSITIONS AND METHODOLOGY FOR DELIVERY OF ALPHA-GALACTOSYLCERAMIDE COMPOUNDS
[French]
COMPOSITIONS ET MÉTHODOLOGIE POUR L'ADMINISTRATION DE COMPOSÉS D'ALPHA-GALACTOSYLCÉRAMIDE
Applicants **
ENGENEIC MOLECULAR DELIVERY PTY LTD
Building 2, 25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066, AU
Inventors
BRAHMBHATT, Himanshu
c/o Engeneic Molecular Delivery PTY Ltd
Building 2, 25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066, AU
MACDIARMID, Jennifer
c/o Engeneic Molecular Delivery PTY Ltd
Building 2, 25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066, AU
Priority Data
63/459,940
17.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1248 | |
| EPO | Filing, Examination | 7058 | |
| Japan | Filing | 529 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3835 |
Total: 13245 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Compositions and methods are described for treating a disease, such as cancer or a viral or bacterial infection. More specifically, the provided compositions comprise encapsulated CD1d-restricted invariant Natural Killer T cell antigen, a bacterial α-galactosylceramide.[French]
L'invention concerne des compositions et des méthodes pour traiter une maladie, comme un cancer ou une infection virale ou bactérienne. Plus spécifiquement, les compositions de l'invention contiennent un antigène de lymphocyte T tueur naturel invariant CD1d restreint encapsulé, un α-galactosylcéramide bactérien.